This notion has been supported by some recently developed anti‐tumour therapies, particularly those that target the NLRP3 inflammasome, such as NLRP3 and IL‐1 inhibitors, which have also been shown to protect the cardiovascular system. The gene discussed is NLRP3; the disease is neoplasm.